PT  - JOURNAL ARTICLE
AU  - Ticau, Simina
AU  - Sridharan, Gautham V
AU  - Tsour, Shira
AU  - Cantley, William L
AU  - Chan, Amy
AU  - Gilbert, Jason A
AU  - Erbe, David
AU  - Aldinc, Emre
AU  - Reilly, Mary M
AU  - Adams, David
AU  - Polydefkis, Michael
AU  - Fitzgerald, Kevin
AU  - Vaishnaw, Akshay
AU  - Nioi, Paul
TI  - Plasma proteome analysis of patients with hereditary transthyretin-mediated (hATTR) amyloidosis establishes neurofilament light chain (NfL) as a biomarker of disease and treatment response
AID  - 10.1101/19011155
DP  - 2019 Jan 01
TA  - medRxiv
PG  - 19011155
4099  - http://medrxiv.org/content/early/2019/12/11/19011155.short
4100  - http://medrxiv.org/content/early/2019/12/11/19011155.full
AB  - Background Hereditary transthyretin-mediated (hATTR) amyloidosis is a rare, progressively debilitating, and fatal disease caused by deposition of aggregated transthyretin amyloid in multiple organs and tissues. Highly variable disease penetrance has made it difficult to predict disease onset and progression. Clinically validated, non-invasive plasma biomarkers may facilitate earlier diagnosis and aid monitoring of disease progression.Methods Plasma levels of >1000 proteins were measured in patients with hATTR amyloidosis with polyneuropathy who received either placebo or patisiran in the phase 3 APOLLO study (NCT01960348) and in a cohort of healthy individuals. The impact of patisiran treatment on the time profile of each protein was determined by a linear mixed model at 0, 9, and 18 months. Neurofilament light chain (NfL) protein was further assessed using an orthogonal quantitative approach.Findings A significant change in the levels of 66 proteins was observed with patisiran vs placebo, with change in NfL, a marker of neuronal damage, most significant (p<10−20). Analysis of the changes in protein levels demonstrated that the proteome of patients treated with patisiran trended towards healthy individuals at 18 months. Plasma NfL levels in healthy controls were four-fold lower than in patients with hATTR amyloidosis with polyneuropathy (16·3 [SD 12·0] pg/mL vs 69·4 [SD 42·1] pg/mL, p<10−16). Levels of NfL at 18 months increased with placebo (99·5 [SD 60·1] pg/mL) and decreased with patisiran treatment (48·8 [SD 29·9] pg/mL). At 18 months, improvement in modified Neuropathy Impairment Score+7 (mNIS+7) in patisiran-treated patients significantly correlated with a reduction in NfL levels (R=0·43, p<10−7).Interpretation The observed correlation of NfL reduction with patisiran treatment and improvement in mNIS+7 suggests it may serve as a biomarker of nerve damage and polyneuropathy in hATTR amyloidosis. This biomarker may enable earlier diagnosis of polyneuropathy in patients with hATTR amyloidosis and facilitate monitoring of disease progression.Competing Interest StatementSimina Ticau, Gautham V Sridharan, Shira Tsour, William L Cantley, Amy Chan, Jason A Gilbert, David Erbe, Emre Aldinc, Kevin Fitzgerald, Akshay Vaishnaw, and Paul Nioi are all employed by Alnylam. Michael Polydefkis has participated in clinical trials sponsored by Alnylam, Ionis and Pfizer and has received consulting fees from Alnylam, Ionis and Pfizer. David Adams has participated in clinical trials sponsored by Alnylam, Ionis and received consulting fees advisory from Alnylam and Pfizer. Mary M Reilly has participated in a clinical trial sponsored by Ionis and has received consulting fees from Alnylam, Ionis and AKCEA.Clinical TrialNCT01960348Funding StatementThis study was sponsored by Alnylam Pharmaceuticals.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot applicable